Search Results
Your search for ,foR matches 32828 pages
Showing 16851 - 16900IMpower 132: Atezolizumab in Combination With Pemetrexed and Platinum-Based Chemotherapy in Advanced Nonsquamous NSCLC
The phase III IMpower132 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of atezolizumab (Tecentriq) plus chemotherapy (cisplatin or carboplatin plus pemetrexed [Alimta]) reduced the risk of disease worsening or death compared to chemotherapy...
Quality-of-Life and Patient-Centered Outcomes With Olaparib Maintenance in Relapsed Ovarian Cancer
In the phase III SOLO2 trial reported in The Lancet Oncology, Friedlander et al found that olaparib maintenance therapy did not worsen health-related quality of life vs placebo in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1 or BRCA2 mutation. In the study, maintenance...
Julie M. Vose, MD, MBA, and David G. Maloney, MD, PhD, on NHL: Update on CAR T-Cell Therapies
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, and David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center and winner of this year’s Oliver Press Memorial Award, discuss three CAR T-cell products for lymphoma treatment, comparing their efficacy, toxicity, ease of ...
Bruce D. Cheson, MD, and Richard I. Fisher, MD, on Lymphoma: Treatment Considerations
Bruce D. Cheson, MD, of Georgetown University Hospital, and Richard I. Fisher, MD, of Fox Chase Cancer Center, discuss ways to incorporate PET and CT scanning into standard of care for and research studies on lymphoma.
Laurie H. Sehn, MD, MPH, on HGBCL With Comorbidities: Upfront Therapies
Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses the challenges of treating high-grade B-cell lymphoma in older patients and those with comorbidities. Several strategies have been devised, but more research is needed as well as more options for novel...
Susan M. O’Brien, MD, on CLL: Sequencing Therapy Options
Susan M. O’Brien, MD, of the University of California, Irvine, discusses three oral agents for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma, and the use of chemotherapy for the disease.
John G. Gribben, MD, DSc, on The Tumor Microenvironment, Prognosis, and Outcome
John G. Gribben, MD, DSc, of the Barts Cancer Institute, discusses how understanding the role of the tumor microenvironment can help identify treatment targets, including combination therapies, and improve outcome for patients with indolent lymphomas.
Kieron M. Dunleavy, MD, on B-Cell Malignancies: Novel-Novel Drug Combinations
Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.
Alan S. Rabson, MD, Long-Time NCI Deputy Director and Cancer Research Stalwart, Dies at Age 92
MANY IN the cancer research and National Institutes of Health (NIH) community are mourning the loss of long-time National Cancer Institute (NCI) senior leader Alan S. Rabson, MD, who died on July 4 at the age of 92. With a distinguished scientific career that spanned 6 decades and included...
NIMHD Selects Recipients of the Minority Health and Health Disparities Research Innovation Award
THE NATIONAL INSTITUTE on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH), has selected recipients of the 2018 William G. Coleman, Jr, PhD, Minority Health and Health Disparities Research Innovation Award. Now in its second year, this competitive...
Pseudosophisticated Language and Needless Confusion?
I’ve been a loyal ASCO member since the early 1970s (aka “back in the day”) and wanted to share a growing pet peeve. I thought of attacking an individual author, but my sense tells me the source of my annoyance is really now a cultural problem and one that can only be fixed at the editor level....
Immunotherapy Gave Me Back My Life
Despite the fact that my father was a smoker and I watched him die a horrible death from lung cancer in the 1970s, until 4 years before my own lung cancer diagnosis in 2012, I, too, was a heavy smoker for most of my adult life. Still, cancer was the farthest thing from my mind when I made an...
Compassionate ASCO Print Resource for Families Facing Serious Illness
The ASCO Answers Advanced Cancer Care Planning booklet contains comprehensive information about how patients can communicate directly and honestly about advanced cancer and end-of-life care with their friends, family, and children, as well as the health-care team. With this expert resource,...
Long-Term Follow-up of Women With DES-Related Vaginal and Cervical Clear Cell Adenocarcinoma
In a letter to the editor of The New England Journal of Medicine, Dezheng Huo, MD, of the University of Chicago, Chicago, and colleagues described the long-term outcomes of women with vaginal and cervical clear cell adenocarcinoma associated with prenatal exposure to the synthetic nonsteroidal...
Risk of Breast Cancer After Negative Screening Mammography
A study reported in JAMA Oncology by Anne Marie McCarthy, PhD, of the Division of General Internal Medicine, Massachusetts General Hospital, and colleagues identified the risk of interval breast cancer after negative screening mammography, including the risk of poor-prognosis breast cancer. The...
Circulating Tumor Cells and Adjuvant Radiotherapy in Early Breast Cancer
In a study reported in JAMA Oncology by Chelain R. Goodman, MD, PhD, of the Department of Radiation Oncology at Northwestern University Feinberg School of Medicine, and colleagues, adjuvant radiotherapy was associated with better outcome in patients with early breast cancer who had detectable...
Multiple-Gene Sequencing vs BRCA1/2-Alone Testing After Breast Cancer Diagnosis
In a retrospective cohort study reported in JAMA Oncology by Allison W. Kurian, MD, of Stanford University School of Medicine, and colleagues found that use of germline multiple-gene sequencing has become more common than BRCA1/2-alone sequencing after breast cancer diagnosis in clinical practice. ...
Journal of Oncology Practice Launches New Blog to Facilitate Discussions on Care Delivery Topics
The Journal of Oncology Practice (JOP) launched a new care delivery blog, JOP DAiS(Discussion & Analysis in Short), to serve as a forum for commentary and analysis on issues affecting the mechanisms of oncology care delivery. This new platform will be a way to collaborate, debate, and discuss...
New International Journal Advances in Cell & Gene Therapy Now Available, Names Editors-in-Chief, Deputy Editors
A NEW INTERNATIONAL JOURNAL, Advances in Cell & Gene Therapy, recently published its inaugural issue in May 2018. The new publication aims to provide a forum for authors to share their newest results, views, and visions in the field of cell and gene therapy. The journal will be published on a...
Bevacizumab Plus Chemotherapy in Advanced Ovarian Cancer
ON JUNE 13, 2018, bevacizumab (Avastin) was granted approval for treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection1,2. The...
Be Prepared to Answer—and Ask—Questions About Integrative Therapy
ASCO HAS ENDORSED the recommendations in the Society for Integrative Oncology (SIO) clinical practice guidelines for integrative therapies during and after breast cancer.1,2 The guidelines “are clear, thorough, and based on the most relevant scientific evidence,” wrote the ASCO expert panel that...
Correction
The article “A Commitment to Innovation, Gender Equality, and Family Legacy Inspire Endowed Young Investigator Award Gifts for ASCO’s Conquer Cancer Foundation” in the May 25, 2018, issue included an incorrect quote attributed to Murdo Gordon. The corrected article is available online at...
ASCO Endorses Guidelines for Integrative Therapies During and After Breast Cancer Treatment
RECOMMENDATIONS IN the Society for Integrative Oncology (SIO) clinical practice guidelines for integrative therapies during and after breast cancer treatment “are clear, thorough, and based on the most relevant scientific evidence,” concluded an ASCO expert panel that reviewed the guidelines.1,2...
ASCO, Conquer Cancer Congratulate 2018 Grant and Award Recipients
ASCO’s Conquer Cancer Foundation presented more than $7.3 million in grants and awards to exceptional oncology researchers at the 2018 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...
Sagar Lonial, MD, on Multiple Myeloma: Sequencing Therapies
Sagar Lonial, MD, of the Emory University School of Medicine, discusses the importance of planning for relapse based on the treatment a patient has received, new targets for refractory myeloma, and the role of cellular therapy.
Andrew D. Zelenetz, MD, PhD, on NHL: Clinical Applications of Genomic Studies
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the various ways genomics can be used in diagnosing and treating non-Hodgkin lymphoma and the need for a proper support tool to help interpret the data.
Julie M. Vose, MD, MBA, on Lymphoma: Novel Pathways for Targeted Agents
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses promising pathways for inhibitors—BTK, PI3K, EZH2, bcl-2—and the clinical trials for single agents and combinations that suggest their potential for lymphoma treatment.
Is the Move to a Value-Based Health-Care Delivery System Feasible?
In 2015, Congress passed the Medicare Access and CHIP Reauthorization ACT (MACRA), which aims to move Medicare toward reimbursement based more on outcomes and values, a goal, in theory, shared by the oncology community. To shed light on the complicated and problematic attempt to restructure the...
Pegfilgrastim-jmdb as Biosimilar to Pegfilgrastim to Decrease Risk of Infection During Cancer Treatment
On June 4, 2018, pegfilgrastim-jmdb (Fulphila) was approved as a biosimilar to pegfilgrastim (Neulasta) to decrease infection risk in patients with nonmyeloid cancer receiving myelosuppressive chemotherapy associated with a significant incidence of febrile neutropenia.1,2 Approval Basis Approval...
No Survival Benefit for Atezolizumab inPD-L1–Positive Urothelial Cancer
As reported in The Lancet by Thomas Powles, MD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III IMvigor211 trial showed no survival benefit for atezolizumab vs physician’s choice of chemotherapy in platinum-treated locally advanced or metastatic urothelial...
Opportunities, Issues, and Challenges for Biosimilars in Oncology
In an article published recently in TheNew England Journal of Medicine, Gary H. Lyman, MD, MPH, FACP, FRCP (Edin), FASCO, of Fred Hutchinson Cancer Research Center in Seattle, and colleagues reviewed opportunities, issues, and challenges posed by the advent of biosimilar medications, focusing on...
When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?
Prior to ASCO’s 2016 endorsement of the Cancer Care Ontario (CCO) guideline on active surveillance in the management of localized prostate cancer,1 most men—over 90%—diagnosed with low-risk localized disease were treated with active therapy.2 Today, about 50% of American men with low-risk disease...
Cost Differences in Chemotherapy Administration by Site
Critics of health-care consolidation have cited higher costs of chemotherapy administration as an example of how mergers drive up costs. A new study by Kalidindi et al in The American Journal of Managed Care found that although drug administration costs in hospitals are higher,...
Loren Rourke, MD, MHCM, Joins US Oncology Network as Chief Surgical Officer
The US Oncology Network (The Network) announced the appointment of Loren Rourke, MD, MHCM, as its Chief Surgical Officer, a new role created to support and enhance the surgical community within The Network. With more than 15 years of surgical experience, Dr. Rourke served as Regional Breast...
Pediatric CT Scans and Subsequent Malignancy Risk
A new study by Meulepas et al in the Journal of the National Cancer Institute suggests that computed tomography (CT) scans may increase the risk of brain tumors. The use of CT scans has increased dramatically over the past 2 decades. CT scans greatly improve diagnostic capabilities,...
FDA Grants Breakthrough Therapy Designation for Atezolizumab/Bevacizumab Combination as First-Line Treatment for Advanced or Metastatic HCC
The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation for atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver...
Second Allogeneic HCT vs Donor Lymphocyte Infusion in Acute Myeloid Leukemia Relapse
In a retrospective registry study reported in JAMA Oncology, Kharfan-Dabaja et al found no overall survival difference with second allogeneic hematopoietic cell transplantation (HCT) vs donor lymphocyte infusion (DLI) in patients with acute myeloid leukemia (AML) relapse. The study involved 418...
Less Toxicity With Pelvic IMRT vs Standard RT in Cervical and Endometrial Cancers
In the phase III NRG Oncology-RTOG 1203 study, patient-reported gastrointestinal (GI) and urinary toxicities were reduced with intensity-modulated radiation therapy (IMRT) vs standard radiotherapy (RT) in women with cervical or endometrial cancer. The findings were reported by Klopp et al in the...
Eric Tetzlaff, MHS, PA-C, DFAAPA, Receives 2018 AAPA Publishing Award
ERIC TETZLAFF, MHS, PA-C, DFAAPA, a physician assistant at Fox Chase Cancer Center, has received the American Academy of Physician Assistants (AAPA) 2018 Publishing Award for his article, “National Study of Burnout and Career Satisfaction Among Physician Assistants in Oncology: Implications for...
Association of American Physicians Welcomes Stephen J. Forman, MD, as Honorary Member
STEPHEN J. FORMAN, MD, the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at the City of Hope Comprehensive Cancer Center, has been inducted as a member of the Association of American Physicians. Dr. Forman has been a leader in the field of ...
Acupressure for Cancer-Related Fatigue
Difficult-to-treat, cancer-related fatigue is a common, distressing clinical issue. It impedes daily activities, severely affecting patients’ quality of life. Compounding the problem is a lack of consensus on an effective pharmacologic intervention. Acupressure is a traditional Chinese medicine...
Olaparib for Germline BRCA-Mutated Metastatic Breast Cancer
EARLY IN 2018, olaparib tablets (Lynparza) were granted regular approval for treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.1,2...
Answers to Hematology Expert Review Questions
Question 1 Which of the following is one of the four major criteria for the diagnosis of essential thrombocythemia? Correct Answer: A. Platelet count ≥ 450 × 109/L. Expert Perspective The diagnosis of essential thrombocythemia requires that all four major criteria or the first three major...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Abiraterone Plus Prednisone in High-Risk Metastatic Castration-Sensitive Prostate Cancer
EARLY IN 2018, abiraterone acetate tablets (Zytiga) in combination with prednisone were approved for the treatment of metastatic high-risk castration-sensitive prostate cancer.1,2 Supporting Efficacy Data APPROVAL WAS based on the findings of the phase III LATITUDE trial, in which 1,199 patients...
Four Generations of Doctors, One Oncologist, in the Family of Hanna K. Sanoff, MD, MPH
Medicine is a family tradition for Hanna K. Sanoff, MD, MPH. “I was born and reared in a suburb just outside of Philadelphia and lived there my whole life until after college. I was one of those people who always knew they wanted to be a doctor. There were four generations of physicians on my...
FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer
ON JULY 13, 2018, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi) for patients with castration-resistant prostate cancer (CRPC). This approval broadens the indicated patient population to include patients with either nonmetastatic CRPC or metastatic CRPC. Enzalutamide was ...
C-Reactive Protein and Radiotherapy Skin Toxicity in Patients With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Hu et al found that higher postradiotherapy levels of the inflammatory marker high-sensitivity C-reactive protein (hsCRP) were associated with an increased risk of early grade 4+ skin toxicity in patients with breast cancer. Study Details...
Risk of Cancer After Treatment of Testicular Germ Cell Cancer
In a Dutch study reported in the Journal of Clinical Oncology, Groot et al found that the risk of subsequent malignant neoplasms was increased in the long-term follow up of patients receiving cisplatin or radiotherapy for testicular germ cell cancer. Risk vs General Population The study involved...
Delayed Skin Effects of Anti–PD-1 Therapy
Patients with cancer receiving anti–programmed cell death protein 1 (anti–PD-1) therapies who develop lesions, eczema, psoriasis, or other forms of autoimmune diseases affecting the skin may experience those adverse reactions on a delay—sometimes even after treatment has...
